Biosante (BPAX) showed some strength today following this news release
http://finance.yahoo.com/news/Ceregene-Advances-Phase-2b-prnews-2562518899.html?x=0&.v=1
Ceregene is a private gene therapy company that BPAX acquired a small ownership interest in from their acquisition of cell genesys $CEGE. The p2b of this Parkinson's disease trial is on pace to be enrolled by June 2011. I wouldn't hold your breath for any material benefit for BPAX- this drug has already failed one p2 trial and this is an altered protocol based on "re-evaluation" of the data...rarely a productive undertaking.Libigel continues to be the sole news driver for BPAX- next update is Feb 12th safety study presentation at a scientific conference. 2011 NDA is going to start looking perilous if there safety study can't stop enrollment soon!
http://finance.yahoo.com/news/Ceregene-Advances-Phase-2b-prnews-2562518899.html?x=0&.v=1
Ceregene is a private gene therapy company that BPAX acquired a small ownership interest in from their acquisition of cell genesys $CEGE. The p2b of this Parkinson's disease trial is on pace to be enrolled by June 2011. I wouldn't hold your breath for any material benefit for BPAX- this drug has already failed one p2 trial and this is an altered protocol based on "re-evaluation" of the data...rarely a productive undertaking.Libigel continues to be the sole news driver for BPAX- next update is Feb 12th safety study presentation at a scientific conference. 2011 NDA is going to start looking perilous if there safety study can't stop enrollment soon!
RSS Feed
